2-(Piperazin-1-yl)quinoline |
Catalog No.GF40253 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4774-24-7
Sample solution is provided at 25 µL, 10mM.
Quipazine shows binding efficacy to 5-HT1 and 5-HT2 with Ki values of 230 nM[3].
Quipazine displaces [3H]GR65630 from 5-HT3R in rat entorhinal cortex with a Ki value of 1.4 nM[3].
Quipazine shows antagonistic properties on the rat vagus nerve with pIC50 value of 6.1, 6.49 and 6.17 for 5-HT2, 5-HT1 and inhibition of 5-HT release[4].
Quipazine (2.5, 5 and 7.5 mg/kg, one dose for once; i.p.) affects dietary self-selection of different macronutrient diets in male and female rats[1].
[1]. Mok E, et al. Effect of quipazine, a selective 5-HT3 agonist, on dietary self-selection of different macronutrient diets in male and female rats. Appetite. 2000 Jun;34(3):313-25.
[2]. G眉nther S, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021 May 7;372(6542):642-646.
[3]. Glennon RA, et al. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
[4]. Ireland SJ, Tyers MB. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol. 1987 Jan;90(1):229-38.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *